Last Updated: August 9, 2026

Details for Patent: 4,861,760

Name: Drug Patent Intelligence for US Patent 4861760
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 4,861,760

Title:	Ophthalmological composition of the type which undergoes liquid-gel phase transition
Abstract:	The present invention relates to a pharmaceutical composition intended for contacting with a physiological liquid characterized in that said composition is intended to be administered as a non-gelled liquid form and is intended to gel in situ, this composition containing at least one polysaccharide in aqueous solution, of the type which undergoes liquid-gel phase transition gelling in situ under the effect of an increase in the ionic strength of said physiological liquid.
Inventor(s):	Claude Mazuel, Marie-Claire Friteyre
Assignee:	CHIBRET INTERNATIONAL SA , Laboratories Merck Sharp and Dohme Chibret SAS , Merck and Co Inc
Application Number:	US06/911,606
Patent Claim Types: see list of patent claims	Composition;

Drugs Protected by US Patent 4,861,760

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 4,861,760

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	85 14689	Oct 03, 1985

International Family Members for US Patent 4,861,760

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0227494	⤷ Start Trial	95C0013	Belgium	⤷ Start Trial
Austria	72990	⤷ Start Trial
Australia	595240	⤷ Start Trial
Australia	6318986	⤷ Start Trial
Canada	1280367	⤷ Start Trial
China	1046094	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.